Please note that any funds granted from the FSHD Canada Foundation cannot be used to cover more than ten percent (10%) of overhead costs.
Biomarkers
Investigators: Yi-Wen Chen (Children’s National Hospital, Washington, DC) Giorgio Tasca & Enzo Ricci (Università Cattolica del Sacro Cuore – Rome) Sabrina Sacconi (Centre Hospitalier Universitaire de Nice) Biomarkers are used…
Read MoreClinical Trial Research Network (CTRN)
Investigators: Jeffrey Statland (University of Kansas Medical Center) and Rabi Tawil (University of Rochester Medical Center) This project includes support for the CTRN to continue the Natural History Studies (MOVE…
Read MoreMuscle targeted immunosuppression as an FSHD therapeutic
Investigator: Andreia Marcelino Nunes, PhD; University of Nevada, Reno School of Medicine FSHD is caused by aberrant increased expression of the DUX4 gene in skeletal myocytes, which initiates a pathogenic…
Read MoreGeneration of porcine large animal models for FSHD therapeutic development and preclinical testing
Investigators: Peter L. Jones Lab; University of Nevada, Reno School of Medicine The primary therapeutic target in all forms of FSHD is DUX4-fl mRNA and DUX4-FL protein, and animal models…
Read MoreMotor Outcomes to Validate Evaluations in FSHD
Investigators: Jeffrey Statland, PI (University of Kansas Medical Center); and Rabi Tawil, Co-PI (University of Rochester Medical Center) The primary goal of this proposal is to hasten therapeutic development for…
Read MoreFacio Therapies
Facio Therapies, established in 2014, is a Netherlands-based company with a single focus – to overcome FSHD by developing a causal therapy that restores the natural repression of muscle-toxic DUX4.…
Read More